TIME COURSE ANALYSIS OF 25 CASE PATIENTS WITH AVIAN INFLUENZA A (H5N1) VIRUS INFECTION IN CHINA, 2005-2007

Ms. Huai Yang

A Thesis Submitted in Partial Fulfillment of the Requirements

for the Degree of Master of Public Health Program in Health Systems Development

College of Public Health Sciences

Chulalongkorn University

Academic Year 2007

Copyright of Chulalongkorn University

502071

| Thesis Title | TIME COURSE ANALYSIS OF 25 CASE PATIENTS WITH |
|------------------|---|
| | AVIAN INFLUENZA A (H5N1) VIRUS INFECTION IN CHINA, |
| | 2005-2007 |
| Ву | Huai Yang |
| Field of Study | Health Systems Development |
| Thesis Advisor | Robert Sedgwick Chapman, M.D., M.P.H. |
| Accepte | d by College of Public Health Sciences, Chulalongkorn University in |
| Partial Fulfillm | ent of the Requirement for the Master's Degree |
| | Dean of College of Public Health Sciences |
| (Pro | fessor Surasak Taneepanichsakul, M.D.) |
| THESIS COMM | MITTEE |
| | Bhu Sm. Chairperson |
| (Ass | istant Professor Ratana Somrongthong, M.A., Ph.D.) |
| Ro | M Sulgnick Chymm Thesis Advisor |
| | pert Sedgwick Chapman, M.D., M.P.H.) |
| V | External Member on Iamsirithaworn, M.D., FETP, M.P.H.) |

PH 072469: MAJOR HEALTH SYSTEMS DEVELOPM

KEY WORDS: HIV / TIME TO VIROLOGICAL SUPPRESSION / TIME TO

VIROLOGICAL FAILURE / PREDICTORS OF VIROLOGICAL

SUPPRESSION AND FAILURE, HAART

JOHN CHARLES LIDDY: TIME TO VIROLOGICAL SUPPRESSION AND SUBSEQUENT FAILURE IN ARV-NAÏVE SUBJECTS RECEIVING HAART: RESULTS FROM THE HIV-NAT OO6 COHORT. THESIS ADVISOR: ROBERT SEDGWICK CHAPMAN, M.D., M.P.H., 94 pp.

A cohort study of virological suppression (to a plasma viral load [pVL] <50 copies), and subsequent virological failure (pVL rebounding to >50 copies), was conducted in antiretroviral therapy-naive HIV patients in Thailand. Effects of time on highly active antiretroviral therapy (HAART) and of other characteristics on likelihood of suppression and failure were assessed with Kaplan-Meier product-limit curves, person-time logistic and Poisson regression, and Cox proportional hazards regression. Analysis included 404 subjects (221 males and 183 females), all of whom achieved suppression and 69 (17.1%) of whom experienced failure afterwards. The time intervals from starting HAART to suppression, and from suppression to failure or end of study, were examined.

Unstratified Kaplan-Meier curves exhibited two inflection points in the time courses of both suppression and failure (slow initial rise, then steep intermediate, then slow final rise). Thus, the time variable was modeled as the cubic polynomial of time on study in person-time regression models. Regressions were run with only the three terms for the time polynomial, yielding unadjusted time effect estimates. Bivariate analysis was conducted to evaluate effects of other independent variables separately on time to suppression and failure. Variables for which P < 0.2 were entered into multivariable regression models, along with the 3 terms for the cubic polynomial of time, yielding adjusted time effect estimates.

Unadjusted and adjusted time effects estimates were highly statistically significant for both suppression and failure (P < 0.001). Furthermore, in both logistic and Poisson regressions, differences between unadjusted and adjusted time effects estimates were very small. These observations confirmed the appropriateness and robustness of modeling time with a cubic polynomial. There was no evidence that longer time was associated with increased likelihood of suppression or failure.

Final multivariable analysis identified a baseline regimen including a PI and a baseline pVL <50 000 as predictive of faster suppression (OR 1.87, P<0.0001, OR 0.713, P=0.005 respectively) while a diagnosis of AIDS before baseline showed a trend to slower suppression (OR 0.87, P=0.085) Females were likely to fail more slowly (OR 0.57, P=0.049) while those with a baseline CD4 count >200 cells and those with a baseline pVL >50 000 copies were more likely to fail more quickly (OR 3.13, P<0.0001 and OR 1.94, P=0.015 respectively). A baseline regimen including a PI and suppressing before week 12 showed a trend to slower failure (OR 0.51, P=0.089 and OR 1.93, P=0.058 respectively. Covariate effects were similar in logistic, Poisson and Cox models.

| Field of Study <u>Health Systems Development</u> | Student's signature_ | _ | |
|--|----------------------|---------|----|
| Academic year 2007 | Advisor's signature | Kobully | am |

ACKNOWLEDGEMENTS

I grateful acknowledge my advisors, Dr. Robert Sedgwick Chapman, Assist Prof. Ratana Somrongthong and Dr. Sopon Iamisirithaworn, for helping me to review my early drafts of the thesis to the final on with care. Their comments, suggestions and guidance have been especially helpful.

I would like to thank Field Epidemiology Training Program (FETP), Ministry of Public Health of Thailand; Chinese Center for Disease Control and Prevention for helping me to initiate this study.

Finally, my intensive study cannot be completed successfully without outstanding effort of academic and administrative staff of the College of Public Health Science, Chulalongkorn University.

TABLE OF CONTENTS

| | Page |
|---|------|
| ABSTRACT. | iii |
| ACKNOWLEDGEMENTS | iv |
| TABLE OF CONTENTS. | v |
| LIST OF TABLES | viii |
| LIST OF FIGURES | x |
| ABBREVIATIONS | xii |
| CHAPTER I INTRODUCTION | 1 |
| 1.1 Background and Significance of the Problem | 1 |
| 1.2 Research Objectives | 9 |
| 1.3 Research Questions | 9 |
| 1.4 Research Hypotheses | 10 |
| 1.5 Variables to be Studied | 11 |
| 1.6 Definitions | 12 |
| CHAPTER II LITERATURE REVIEW | 14 |
| 2.1 Avian influenza (H5N1) Surveillance System | 14 |
| 2.2 Epidemiology and Clinical | 19 |
| 2.3 Risk Factors of Human Infect with H5N1 | 23 |
| 2.4 Laboratory Tests for H5N1 Virus | 25 |
| 2.5 WHO Guidelines on Avian Influenza A (H5N1) Cases Report | 27 |
| CHAPTER III METHODS | 30 |
| 3.1 Research Design | 30 |
| 3.2 Research Setting | 31 |

| | Page |
|--|------|
| 3.3 Research Population | 31 |
| 3.4 Data Source | 32 |
| 3.5 Data Collection | 32 |
| 3.6 Laboratory Assay | 33 |
| 3.7 Training for Investigators and Pre-Test of Questionnaire | 34 |
| 3.8 Database and Analysis | 34 |
| 3.9 Ethical Review | 45 |
| CHAPTER IV RESEARCH RESULTS | 46 |
| 4.1 Patients and Contact History | 46 |
| 4.2 Clinical Time Course | 48 |
| 4.3 Case Detection and Reporting | 52 |
| 4.4 Virological Testing | 52 |
| CHAPTER V CONCLUSIONS AND RECOMMENDATIONS | 56 |
| 5.1 Discussion | 56 |
| 5.2 Limitations | 59 |
| 5.3 Conclusions and Recommendations | 60 |
| REFERENCES | 62 |
| APPENDICES | 69 |
| APPENDIX A: Informed Consent Form for the HIVNAT 006 Study | 70 |
| CURRICULUM VITAE | 72 |

LIST OF TABLES

| Pag | e |
|--|----|
| Table 1-1: Data management of timeline study for AI human cases in China, | |
| 2005 20073 | 6 |
| Table 1-2: Data analyze plan of timeline study for AI human cases in China, | |
| 2005-2007 | 7 |
| Table 2: Estimation of incubation period of human cases infection with avian | |
| influenza A (H5N1) virus, 2005-2007, China | 8 |
| Table 3: Timeline of medical consultation and admission of 25 H5N1 cases, China, | |
| October 2005 – December 2007 | 1 |
| Table 4: Timeline of case reporting and confirmation of 25 H5N1 cases, China, | |
| October 2005 – December 2007 | 2 |
| Table 5: Time and location of respiratory specimens' collection associated with | |
| H5N1 virus isolation positive | ;4 |
| Table 6: Evaluation of PCR for Avian Influenza A (H5N1) virus in respiratory | |
| samples | 55 |

LIST OF FIGURES

| Page |
|--|
| Figure 1: Map of areas reporting confirmed occurrence of Avian Influenza |
| A (H5N1) in poultry and wild birds since 20033 |
| Figure 2: Map of areas with confirmed human cases of Avian Influenza A (H5N1) |
| since 20034 |
| Figure 3: Confirmed cases of human infection with Avian Influenza A (H5N1), by |
| date of onset - China, 2005 – 20085 |
| Figure 4: Map of confirmed cases of human infection with Avian Influenza |
| A (H5N1), China, 2005 – 20076 |
| Figure 5: Conceptual framework of study design and data collection |
| Figure 6-1: Timeline of disease in human infection with Avian Influenza |
| A (H5N1), China, 2005-200730 |
| Figure 6-2: Timeline of disease confirmation and report in human with Avian |
| Influenza A (H5N1) infection, China, 2005-200731 |

ABBREVIATIONS

CFR Case Fatality Rate

China CDC Chinese Centers for Disease Control and Prevention

CI Confidence Intervals

CRBC Chicken Red Blood Cells

CRF Case Report Form

GRBC Guinea Pig Red Blood Cells

HI Hemagglutination Inhibition

HCWs Health Care Workers

HPAI Highly Pathogenic Avian Influenza

HRBC Horse Red Blood Cells

ICF Informed Consent Form

ILI Influenza Like Illness

IRB Institutional Review Board

MN Microneutralization

NIC National Influenza Center

PI Principal Investigator

RT-PCR Reverse Transcriptase-Polymerase Chain Reaction

SOP Standard Operating Procedure

WHO World Health Organization